In this episode of Investment Research Radio, Ray Crowley sits down with Dr. Ben Holmes, Co-Founder and CEO of Nanochon, a medical technology company developing next generation orthopedic implants designed to repair damaged cartilage and potentially offer an alternative to more invasive joint replacement procedures.
Nanochon is developing Chondrograft, a synthetic, 3D printed implant designed to restore cartilage function in patients suffering from focal cartilage defects and early-stage osteoarthritis. Using proprietary biomaterials and advanced manufacturing techniques, the technology aims to address a significant gap in orthopedic care, particularly for younger and active patients who may not be ideal candidates for total knee replacement.
Dr. Holmes discusses the origins of Nanochon, the science behind its implant technology, and the journey from university research and biomedical engineering to clinical development and commercialization.
They explore the company's preclinical research, including animal studies, its progression into first-in-human clinical trials, and the regulatory and clinical milestones required to bring an innovative orthopedic implant to market. They also discuss the broader market opportunity for cartilage repair, the challenges of building and financing a medical device company, and Nanochon's longer-term vision for expanding its technology across additional joints and orthopedic applications.